You are here

WHO trial to assess other antibody, antiviral drugs after remdesivir doubt

nz_remdesivir_171091.jpg
The World Health Organization (WHO) said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential Covid-19 treatments, after the trial found Gilead Science's remdesivir had no impact on survival rates.

[GENEVA] The World Health Organization (WHO) said on Friday it would assess monoclonal antibodies and other antiviral drugs in its trial of potential Covid-19 treatments, after the trial found Gilead Science's remdesivir had no impact on survival rates.

WHO director-general Tedros Adhanom...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes